Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
ConclusionsVIR-2218 showed favorable pharmacokinetics in healthy volunteers supportive of subcutaneous dosing and continued development in patients with chronic HBV infection.Clinical Trial Registration NoNCT03672188, September 14, 2018.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Biotechnology | Chemistry | Clinical Trials | Drugs & Pharmacology | Hepatitis | Hepatitis B | Liver | Study | Urology & Nephrology